IFNG and neoplasm: These results suggest that the treatment of MCA304 and 4T1 tumor-bearing mice with murine IL-13Rα2 DNA and the ECDα2 boost vaccination induced or amplified a specific CTL response and IFN-γ release against sarcoma and breast tumors in the established tumor setting.